Evaluation of clinical and radiological response with antiangiogenic therapy in advanced hepatocellular carcinoma patients

Abstract

Background: Sorafenib represents the primary therapeutic option for people diagnosed with advanced hepatocellular carcinoma (HCC). Nevertheless, it is linked to a range of drug-related negative effects, impacting all cases having low objective response rates along with limited survival prolongation. This work was aimed at assessing the correlation between the early clinical response following a two-week period of Sorafenib therapy and the outcomes in patients with advanced HCC. Methods: The prospective, observational and non-interventional study included 20 cases, with ages above 18 years, both sexes, developing typical HCC, hyper vascular HCC in the liver at baseline, Child-Pugh class A disease as regards liver function along with eastern cooperative oncology group performance status of 0 or 1. Triphasic-computed tomography (CT) images were obtained for all patients at baseline, within two and six weeks following Sorafenib administration, and then every 8 weeks till 6 months. Results: Our prompt evaluation of Sorafenib treatment demonstrated a favorable overall survival rate (p